Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis

Figure 1

Plasma ascorbic acid levels following intravenous infusion of ascorbic acid. Plasma ascorbic acid levels were subnormal at entry (<50 μM, dotted line). Ascorbic acid levels rose rapidly in the two treatment groups and were significantly higher than placebo within twelve hours (Lo-AscA vs. placebo p < 0.005, Hi-AscA vs. placebo p < 0.0005) remaining consistently elevated for 96 hours. Ascorbic acid levels in the Hi-AscA group were significantly higher than the Lo-AscA group from the 12 hour point forward. These data show that an intermittent ascorbic acid infusion protocol (every 6 hours) produces sustained steady state levels in patients with severe sepsis. Placebo (О), Lo-AscA (), Hi-AscA (▲).

Back to article page